Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea

M. Marchini, L. Fedele, U. Garagiola, V. Maresca

Research output: Contribution to journalArticle

Abstract

In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p

Original languageEnglish
Pages (from-to)699-705
Number of pages7
JournalDrugs under Experimental and Clinical Research
Volume13
Issue number11
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea'. Together they form a unique fingerprint.

  • Cite this